Treatment with plerixafor in a mouse model of metastatic breast cancer revealed that plerixafor reduced stromal cancer-associated fibroblasts—which play an important role in drug resistance and immune exclusion, reduced hypoxia, and fibrosis-related genes like Tgfβ1, while increasing the expression of activated immune-related genes like interferon gamma (IFNγ) and granzymes A and B [222]. Here, IFNG is linked to breast carcinoma.